Korea South
T&R Biofab is a pioneer in the field of 3D bioprinting, utilizing stem cells and biomaterials to develop innovative biomedical solutions for tissue engineering and medical devices. Founded in 2013 in South Korea, the company has made significant strides in the production of biodegradable scaffolds, bio-ink, 3D organoid models, cytotherapeutic agents, and artificial organs. With a focus on research and development, T&R Biofab has secured over 100 patents and expanded their areas of expertise to include the use of induced pluripotent stem cells and specialized biomaterials.
Under the leadership of CEO Dr. Wonsoo Yun, the company has set out to alleviate the suffering of individuals through groundbreaking biomedical technology. Their achievements have been recognized in top scientific journals, including Biofabrication, Biomaterials, Small, Nature Communications, and Advanced Materials. T&R Biofab has also ventured into partnerships with key industry players to develop patient-specific implants and other confidential applications, with a vision to revolutionize healthcare and tissue engineering.
With a growing focus on organ reconstruction and cell therapy applications, including liver reconstruction and CAR T cell therapy, T&R Biofab is positioned as an influential player in the biomedical landscape. The company received an equity investment from DAYLI Partners post-IPO on January 01, 2019, signaling confidence from the investment community in T&R Biofab's potential to transform the biomedical world. As the company continues to innovate and expand its portfolio, it presents an exciting opportunity for investors to join in shaping the future of healthcare and bioprinting. #TnRBiofab #TissueEngineering #Healthcare #Bioprinting #MedicalDevices #CellTherapy
